Expert Ratings
Easily search Stocks, Mutual Funds, eBooks, Articles and Videos
Track the companies of Group.
| Sales Growth | Profit Growth | Expense Growth | Stock Price CAGR |
|---|---|---|---|
Presentation & Earning Calls |
Annual Reports |
Credit Rating |
|---|---|---|
|
|
|
|
Suraksha Diagnostic Limited was incorporated as ‘Suraksha Diagnostic Private Limited’ as a private limited company under the Companies Act, 1956 pursuant to a certificate of incorporation dated March 15, 2005, issued by the Deputy Registrar of Companies, West Bengal at Kolkata (RoC). Subsequently, the company was converted into a public limited company pursuant to a special resolution passed in the extra-ordinary general meeting of its Shareholders held on June 5, 2024, and consequently, the name of the company was changed to ‘Suraksha Diagnostic Limited’, and a fresh certificate of incorporation dated July 16, 2024, was issued by the Registrar of Companies, Central Processing Centre.
The company offers one-stop integrated solutions for pathology and radiology testing and medical consultation services including X-rays, ultrasonography, computerized tomography, magnetic resonance imaging scans and vaccination services through its operational network, consisting of its flagship central reference laboratory, 8 satellite laboratories (co-located with its diagnostic centers) and 215 customer touchpoints which include 49 diagnostic centres, and 166 sample collection centres (primarily franchised), as of June 30, 2024 across the states of West Bengal, Bihar, Assam, and Meghalaya. It generates revenue primarily through sales of its diagnostic services. It also provides vaccination services, and a broad spectrum of customized test packages, aimed at prediction/early detection of diseases.
In addition to integrated pathology and radiology testing services, it also offers omnichannel medical consultation services via online and offline modes to its customers. The doctors at its polyclinics range across specialties and super-specialties such as cardiology, pediatrics, dermatology, rheumatology, oncology, and nephrology. Its model of polyclinic chambers housed in diagnostic centres providing medical consultation services enables patient convenience through holistic integration of services and offering it the first right to a patient’s prescription leading to higher cross-selling opportunities to the company. It derives the majority of its revenues from the B2C segment.
Business area of the company
The company is primarily engaged in the business of running diagnostic centres for carrying out various pathological and radiological services.
Diagnostic services of the company
Awards, accreditations, and recognition
History and milestones
Comment